Efficacy and Safety of Subcutaneous Amifostine in Minimizing Radiation-Induced Toxicities in Patients Receiving Combined-Modality Treatment for Squamous Cell Carcinoma of the Head and Neck

International Journal of Radiation Oncology Biology Physics

Volumn 69, Issue 5, 2007, Pages 1361-1368

  Law, Amy ^a   Kennedy, Thomas ^a   Pellitteri, Phillip ^a   Wood, Craig ^a   Christie, Douglas ^a   Yumen, Omar ^a  

^a GEISINGER MEDICAL CENTER   (United States)

Author keywords

Amifostine; Chemoradiotherapy; Cutaneous reactions; Head and neck cancer; Subcutaneous

Indexed keywords

CHEMOTHERAPY; DISEASES; FRACTIONATION; RADIOTHERAPY;

AMIFOSTINE; CHEMORADIOTHERAPY; CUTANEOUS REACTIONS; SUBCUTANEOUS;

ONCOLOGY;

AMIFOSTINE; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; ONDANSETRON; PACLITAXEL; PARACETAMOL; RANITIDINE;

ADULT; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK CANCER; HUMAN; INJECTION SITE REACTION; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RASH; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; THROMBOCYTOPENIA; UNITED STATES; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; AGED; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MUCOSITIS; PACLITAXEL; PROSPECTIVE STUDIES; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY DOSAGE; XEROSTOMIA;

EID: 36148988380     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.05.052     Document Type: Article

References (31)

1. Brizel D.M. Radiotherapy and concurrent chemotherapy for the treatment of locally advanced head and squamous cell carcinoma. Semin Radiat Oncol 8 (1998) 237-246
2. Kramer S., Gelber R.D., Snow J.B., et al. Combined radiation therapy and surgery in the management of head and neck cancer: Final report of study 73-03 of the Radiation Therapy Oncology Group. Head Neck Surg 10 (1987) 19-30
3. Jeremic B., Shibamoto Y., Stanisavljevic B., et al. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: A prospective randomized trial. Radiother Oncol 43 (1997) 29-37
4. Jassem J., and Bartelink H. Chemotherapy in locally advanced head and neck cancer: A critical reappraisal. Cancer Treat Rev 21 (1995) 447-462
5. El-Sayed S., and Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. Meta-analysis of prospective and randomized trials. J Clin Oncol 14 (1996) 838-847
6. Pignon J.P., Bourhis J., Domenge C., et al. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of Chemotherapy on Head and Neck Cancer. Lancet 355 (2000) 949-955
7. Al-Sarraf M., Leblanc M., Giri P.G., et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol 16 (1998) 1310-1317
8. Calais G., Alfonsi M., Bardet E., et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91 (1999) 2081-2086
9. Adelstein D.J., Lavertu P., Saxton J.P., et al. Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer 88 (2000) 876-883
10. Brizel D.M., Albers M.E., Fisher S.R., et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338 (1998) 1798-1804
11. Olmi P., Crispino S., Fallai C., et al. Locoregionally advanced carcinoma of the oropharynx: Conventional radiotherapy vs accelerated hyperfractionated radiotherapy vs concomitant radiotherapy and chemotherapy-a multicenter randomized trial. Int J Radiat Oncolo Biol Phys 55 (2003) 78-92
12. Wasserman T.H., Brizel D.M., Henke M., et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head and neck cancer: 2-year followup of a prospective, randomized, phase III trial. Int J Radiat Oncol Biol Phys 63 (2005) 985-990
13. Rose-Ped A.M., Bellm L.A., Epstein J.B., et al. Complications of radiation therapy for head and neck cancers. The patient's perspective. Cancer Nurs 25 (2002) 461-467
14. MedImmune Oncology. Ethyol. Amifostine for injection (2005), MedImmune Oncology, a subsidiary of MedImmune, Gaithersburg, MD
15. Brizel D.M., Wasserman T.H., Henke M., et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18 (2000) 3339-3345
16. Koukourakis M.I., Kyrias G., Kakolyris S., et al. Subcutaneous administration of amifostine during fractionated radiotherapy: A randomized phase II study. J Clin Oncol 18 (2000) 2226-2233
17. Bardet E., Martin L., Calais G., et al. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Semin Oncol 29 (2002) 57-60
18. Anne P.R., and Curran Jr. W.J. A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer. Semin Radiat Oncol 12 (2002) 18-19
19. Cooper J.S., Pajak T.F., Forastiere A.A., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350 (2004) 1937-1944
20. Bernier J., Domenge C., Ozsahin M., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350 (2004) 1945-1952
21. Fallai C., Bolner A., Signor M., et al. Long-term results of conventional radiotherapy versus accelerated hyperfractionated radiotherapy versus concomitant radiotherapy and chemotherapy in locoregionally advanced carcinoma of the oropharynx. Tumori 92 (2006) 41-54
22. Chao K.S., Deasy J.O., Markman J., et al. A prospective study of salivary function sparing in patients with head and neck cancers receiving intensity-modulated or three-dimensional radiation therapy: Initial results. Int J Radiat Oncol Biol Phys 49 (2001) 907-916
23. Nakamura J., Shaw L.M., and Brown D.Q. Hydrolysis of WR2721 by mouse liver cell fractions. Radiat Res 109 (1987) 143-152
24. Shaw L.M., Turrisi A.T., Glover D.J., et al. Human pharmacokinetics of WR-2721. Int J Radiat Oncol Biol Phys 12 (1986) 1501-1504
25. Calabro-Jones P.M., Fahey R.C., Smoluk G.D., et al. Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721. Int J Radiat Biol Relat Stud Phys Chem Med 47 (1985) 23-27
26. Culy C.R., and Spencer C.M. Amifostine: An update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs 61 (2001) 641-684
27. Koukourakis M.I. Amifostine in clinical oncology: Current use and future applications. Anticancer Drugs 13 (2002) 181-209
28. Antonadou D., Pepelassi M., Synodinou M., et al. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 52 (2002) 739-747
29. Bardet E., Martin L., Calais G., et al. Subcutaneous (SbQ) versus intravenous (IV) administration of amifostine for head and neck (HN) cancer patients receiving radiotherapy (RT): Preliminary results of the GORTEC 2000-02 randomized trial (Abstr.). Int J Radiat Oncol Biol Phys 63 (2005) S127
30. Thorstad W.L., Chao K.S., and Haughey B. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer. Semin Oncol 31 Suppl. 18 (2004) 8-12
31. Boccia R., Anne P.R., Bourhis J., et al. Assessment and management of cutaneous reactions with amifostine administrations: Findings of the Ethyol (amifostine) cutaneous treatment advisory panel (ECTAP). Int J Radiat Oncol Biol Phys 60 (2004) 302-309